# SS-31 Peptide Dosage, Protocol, and CLinical Evidence Guide

SS-31 is the only peptide in this class with FDA approval — granted in 2025 as Forzinity for Barth syndrome, a rare mitochondrial cardiomyopathy⁹. What earned that approval is also what makes it relevant off-label: SS-31 is structural repair for the mitochondria you already have, rather than pharmacological override.

The distinction from [MOTS-c](/content/mots-c) matters: MOTS-c retrains metabolic signaling (build more mitochondria, burn fat differently), while SS-31 fixes existing infrastructure. In the [Mito Stack](/content/mito-stack-protocol), they're complementary — and [NAD+](/content/nad-guide) provides the redox currency both consume.

Where SS-31 has the strongest case: chronic fatigue where mitochondrial membrane damage is the bottleneck, support during GLP-1 fat loss protocols, and as the structural foundation of the Mito Stack.

## At a Glance

| | |
| --- | --- |
| **Dosage** | 6 mg subcutaneous daily through week 8, then 6 mg daily or 2–3× per week. |
| **Protocol** | Establishment: 6 mg daily through week 8.<br>Extension: continue daily while the response is still building, or move to 2–3× per week once stable. Total course: 8–12+ weeks. |
| **Results timeline** | Target engagement is measurable within hours. The slower structural response builds across weeks 4–8, and human mitochondrial-dysfunction data show continued improvement between weeks 12 and 24 before flattening. |
| **Side effects** | Transient warmth or flushing on early doses, brief nausea that resolves quickly, and mild fatigue early in the daily phase if baseline mitochondrial function is poor. |
| **Regulatory status** | FDA approved as Forzinity for Barth syndrome (2025). Investigational for all other uses. |
| **Best stacked with** | [MOTS-c](/content/mots-c), [NAD+](/content/nad-guide) — see [Mito Stack](/content/mito-stack-protocol).<br>[GLP-1 agonists](/content/semaglutide) for mitochondrial support during rapid fat loss.<br>[L-Carnitine injectable](/content/l-carnitine) to ensure substrate reaches repaired mitochondria. |

---

## What Is SS31 (Elamipretide)?

SS31 — also written SS-31 and known pharmaceutically as elamipretide (trade name Forzinity) — is a short peptide that concentrates inside mitochondria at levels roughly 5,000 times higher than surrounding tissue¹. This selective accumulation is what makes it effective: it reaches the inner membrane where energy production happens, not just the cell in general.

Its target is cardiolipin, a lipid unique to the inner mitochondrial membrane that holds the energy-producing protein complexes in position¹. The [mechanism section below](#how-ss-31-works) covers what happens when cardiolipin is damaged and how SS-31 restores it.

---

## How Mitochondria Break Down

The inner mitochondrial membrane loosens over time under normal life pressures. Each force is small, but together they erode the structure energy production depends on:

| Stressor              | Mechanism                                                                               |
| --------------------- | --------------------------------------------------------------------------------------- |
| Chronic inflammation  | Daily immune activity strains membrane lipid anchors                                    |
| Illness/infection     | Fever and immune response push mitochondria to maximum output                           |
| Poor metabolic health | Glucose swings and insulin resistance force harder work on weakened scaffold            |
| Alcohol               | Even moderate intake generates byproducts challenging membrane stability                |
| Sleep disruption      | Deep sleep is when membrane repair runs; fragmented sleep leaves restoration incomplete |
| Psychological stress  | Stress hormones increase demand while suppressing repair windows                        |
| Age                   | Cumulative exposure to all of the above                                                 |

The result is familiar: effort feels costlier, recovery takes longer, and energy becomes easier to disrupt — not because fuel is lacking, but because the membrane scaffolding has weakened.

---

## How SS-31 Works

SS-31 carries a net positive charge, and the inner mitochondrial membrane presents negatively charged lipid surfaces — cardiolipin prominent among them, alongside phosphatidylglycerol. The peptide partitions into those surfaces by charge attraction rather than docking a specific receptor, and the interaction is not exclusive to cardiolipin. What follows in model systems is a change in the environment the respiratory machinery operates in¹:

**Electron flow becomes cleaner:** The energy-producing protein complexes (respiratory complexes) remain in position, reducing turbulence in the chain and minimizing electron leak¹.

**The membrane holds its charge more reliably:** A tighter membrane sustains the charge difference across the membrane (electrochemical gradient) required for continuous ATP production¹.

**Mitochondria experience less internal strain:** Cleaner flow produces fewer damaging byproducts (reactive oxygen species), allowing each mitochondrion to function longer before requiring replacement¹.

**Tissues meet demand with less effort:** When machinery moves electrons efficiently, work produces proportionate fatigue rather than exaggerated strain.

These are structural corrections, not forced output. SS-31 does not stimulate the system — it restores the architecture that makes clean energy possible.

---

## SS-31 Benefits

### Energy stability

When the membrane is restored, energy becomes more predictable under load. Physical effort produces proportional fatigue instead of delayed crashes. Recovery windows shorten because tissues can power repair programs cleanly rather than working against internal inefficiency.

Daily variability narrows. A poor night's sleep, a missed meal, or a mild illness still registers, but the impact is smaller because the underlying machinery remains stable.

### ATP production in aging

Human studies confirm SS-31 reaches its target and improves function in aging tissue. A single IV dose increased skeletal-muscle ATP production in older adults⁴ — demonstrating target engagement in the population most affected by mitochondrial decline.

### Cardiac function

In failing human heart tissue, SS-31 exposure improved mitochondrial respiration⁵. In Barth syndrome (a genetic disorder of cardiolipin remodeling), the randomized crossover missed its endpoints, but the open-label extension showed strength and cardiac-biomarker improvement sustained over years — and that trajectory, not the randomized data, is what carried FDA approval⁹.

### NAD+ conservation

SS-31 reduces the cellular "NAD+ burn rate" by fixing structural problems that waste it¹. When the membrane is stable:

- Electron flow stops leaking, reducing oxidative byproducts
- The DNA-repair penalty shrinks — the enzyme that consumes NAD+ during oxidative damage repair (PARP) has less work to do
- Inflammatory signals quiet down, so the NAD+-degrading enzyme (CD38) stays low

Net effect: NAD+ levels stay higher because cells spend far less of it cleaning up membrane damage.

---

## Who SS-31 Benefits

SS-31 is used when life loads the mitochondrial membrane beyond its ability to maintain structure. Across these contexts, the principle is the same:

| Profile                 | Why SS-31 Helps                                                                                  |
| ----------------------- | ------------------------------------------------------------------------------------------------ |
| Aging adults            | Restores membrane tension that declines with age; stabilizes daily energy                        |
| GLP-1/retatrutide users | Protocol support for mitochondrial hardware during rapid fat loss; the Retatrutide FAO signal is measured, but the SS-31 combination is not¹¹ |
| Low-energy phenotypes   | Addresses structural instability underlying chronic fatigue and post-exertional malaise          |
| Post-viral recovery     | Re-establishes clean energy production after immune activation stresses membranes                |
| High physical demand    | Athletes, shift workers, sustained cognitive load — reduces mitochondrial strain accumulation    |
| Hormonal transition     | Peri-menopause, andropause — stabilizes energy under increased inflammatory and sleep disruption |

---

## Dosing

SS-31 runs on a fast membrane-engagement clock and a slower structural clock. The protocol uses daily delivery across the full measured establishment window, then adjusts frequency according to whether the response is still building or has stabilized.

**Reconstitution note:** Use bacteriostatic water with sodium chloride (isotonic) to reduce injection site sting and prevent welts. The [peptide reconstitution calculator](/tools/calculator) calculates the BAC-water volume and resulting injection draw for the vial.

### Standard protocol

| Phase | Dose | Duration |
| --- | --- | --- |
| Establishment | 6 mg daily | Weeks 1–8 |
| Extension | 6 mg daily or 2–3× per week | Week 9 onward |

Six milligrams is the direct healthy-adult anchor: SPISC-101 administered 6 mg SubQ daily for seven days and measured the parent compound and both metabolites, with minimal parent accumulation by day 7⁹. Daily dosing continues through week 8 because the slower structural response took four to eight weeks to emerge. After week 8, daily dosing serves a response that is still building; 2–3× weekly is the maintenance option once the response is stable.

### Timing

Dose once daily during the first eight weeks. Morning is a practical default; consistency matters more than timing it to a specific stressor.

### Administration

Subcutaneous injection. Reported adverse events were mild — transient warmth or brief nausea on early doses.

For site rotation, true SubQ depth, and reaction-mitigation guidance, see [where to inject SS-31](/content/where-to-inject-peptides#mots-c-and-ss-31).

### How long before it works, and what happens when you stop

SS-31 runs on two clocks, and confusing them is the most common way people misjudge it.

- **Fast clock — hours to days.** Membrane and redox effects follow the drug and reverse once it clears. This is what a single dose or a short trial buys.
- **Slow clock — 4 to 8 weeks.** The structural change is the point of the protocol. In aged-animal work, nothing measurable appeared at four weeks and the effect was significant at eight, in the same animals on the same test¹⁰.

Three practical consequences:

| Question | Answer |
| --- | --- |
| When to judge it | Week 8, not week 4 |
| What a week-4 null means | Uninformative — the slow phase has not arrived |
| What happens after week 8 | Continue daily if response is building; move to 2–3× weekly once stable |

The offset matters as much as the onset. After treatment stopped, the gain held at two weeks off and had dropped by roughly half at four weeks off¹⁰. That supports maintenance dosing rather than a scheduled break. An 8–12+ week course is the frame: eight weeks is the establishment floor, while week 12 is a reassessment point rather than a hard stop. In the human Barth extension, improvement continued between weeks 12 and 24 before flattening³.

One limit worth stating: those onset and decay numbers come from animals dosed by continuous infusion, while people inject intermittently. Treat 4-to-8 weeks as the shape of the response, not a precise schedule.

**A Day 3–4 pattern is common early in the daily phase.** The first three days often feel flat or mildly fatigued — the working explanation is that mitochondria are stabilizing structure rather than producing output. The shift typically arrives on day four or five: steadier energy, cleaner recovery, less oxidative flare after stress. Users who stop during the early fatigue window often look like non-responders but were mid-adaptation.

---

## Clinical Research and FDA Approval

### Barth syndrome (FDA approved)

SS-31 (as elamipretide/Forzinity) received FDA accelerated approval in September 2025 for Barth syndrome — a genetic disorder defined by defective cardiolipin remodeling². This makes it the first mitochondria-targeted therapeutic approved in the United States.

The randomized portion of TAZPOWER missed both primary endpoints (p=0.97 and p=0.89), and controlled dynamometry did not separate. What carried the approval was the open-label extension: knee-extensor strength improved on a multi-year trajectory, backed by an external-control analysis. FDA reviewers disagreed with the signatory over whether that isolated a treatment effect. Accelerated approval went through on the intermediate endpoint, with confirmation required³. A confirmatory post-marketing study is ongoing.

### Other conditions (investigational)

| Indication                     | Trial         | Result                                                                  |
| ------------------------------ | ------------- | ----------------------------------------------------------------------- |
| Primary mitochondrial myopathy | MMPOWER-3     | Primary endpoint not met; secondary outcomes showed directional benefit⁶ |
| Older adults                   | ATPmax study  | Single IV dose increased skeletal-muscle ATP production⁴                 |
| Dry AMD                        | ReCLAIM-2     | Mixed results overall; functional signal in predefined subgroups         |
| Failing human heart            | Ex vivo study | Improved mitochondrial respiration in human myocardium⁵                  |

Across studies, the mechanistic signal is consistent: SS-31 reaches its target, stabilizes the membrane, reduces byproduct formation, and improves efficiency¹. Functional outcomes vary by indication, but structural effects are reproducibly observed.

---

## SS-31 + MOTS-c + NAD+ Stack

Mitochondrial performance depends on three things: structure, signaling, and cofactor availability.

| Component                  | Role                                                                 |
| -------------------------- | -------------------------------------------------------------------- |
| SS-31                      | Repairs structure — electrons flow cleanly                           |
| [MOTS-c](/content/mots-c)  | Activates adaptive signaling — more mitochondria, better fuel choice |
| [NAD+](/content/nad-guide) | Supplies cofactor — the redox currency mitochondria run on           |

Together: better engines (SS-31) + more engines (MOTS-c) + fuel for both (NAD+). Each arm targets a different axis of the same system — structure, number, and cofactor supply.

This combination is known as the **Mitochondrial Integration & Transformation Triad (MITT)**. See: [Mitochondrial Stack](/content/mito-stack-protocol)

---

## Side Effects and Safety

**Common:**

- Transient warmth or flushing (early doses)
- Brief nausea (typically resolves quickly)
- Mild fatigue early in the daily phase (reflects repair process)

**Rare:**

- No serious adverse events dominant in published trials

The Barth syndrome trials — which included extended treatment over years — showed acceptable tolerability⁹. The FDA approval reflects a positive benefit-risk assessment in a population with severe mitochondrial dysfunction.

---

## Regulatory Status

**FDA approved:** Elamipretide (trade name Forzinity) received accelerated approval in 2025 for Barth syndrome⁹. This is the first mitochondria-targeted drug approved in the US. A confirmatory post-marketing study is required under the accelerated-approval framework.

**Other indications:** For all non-Barth uses, elamipretide remains investigational. Access occurs through expanded-access programs and investigator-led protocols.

**Why limited approvals:** The constraint is economic — developing a specialized mitochondrial therapeutic across diverse chronic conditions is costly. The Barth syndrome approval reflects a focused strategy on a well-defined genetic population.

---

## FAQ

### What is SS-31?

SS-31 (also written SS31, and known pharmaceutically as elamipretide or Forzinity) is a tetrapeptide that targets the inner mitochondrial membrane¹. Unlike metabolic stimulants, SS31 works by repairing structure — specifically by binding and stabilizing cardiolipin, the lipid that holds the electron transport chain in position. The result is cleaner energy production with fewer byproducts. In September 2025, it became the first mitochondria-targeted drug approved by the FDA (for Barth syndrome)².

### What does SS-31 do?

SS-31 associates with the negatively charged lipid surfaces of the inner mitochondrial membrane, cardiolipin among them, and changes the environment the respiratory machinery sits in. In model systems that produces cleaner electron flow, more efficient ATP production, and fewer oxidative byproducts. It acts on membrane structure rather than by stimulating a pathway.

### When are effects reported with SS-31?

Effects begin rapidly — target engagement is measurable within hours. The slower structural response develops across weeks 4–8, which is why the protocol stays daily through week 8 before frequency can drop for maintenance.

### Is SS-31 FDA approved?

Yes, for Barth syndrome under the trade name Forzinity (September 2025). For all other uses, it remains investigational.

### What evidence links SS-31 with aging-related outcomes?

Published data shows SS-31 improves ATP production in aging muscle and reduces markers of mitochondrial inefficiency⁴. It's used intermittently — short repair phases spaced through the year — to restore alignment and maintain steadier daily output.

### How is SS-31 different from MOTS-c?

SS-31 repairs mitochondrial structure (the hardware). MOTS-c activates adaptive signaling to build more mitochondria and improve fuel selection (the software). They're complementary — most effective when combined with NAD+ support.

### What SS-31 dosing ranges and protocol structures have been studied?

The FoxAI protocol uses 6 mg SubQ daily through week 8 of an 8–12+ week course. After week 8, continue 6 mg daily while the response is still building or move to 6 mg 2–3 times per week once stable. Six milligrams has direct healthy-adult repeated-dose PK, while the eight-week daily phase spans the measured structural establishment window⁹ ¹⁰.

### How is SS-31 reconstituted and stored?

Reconstitute with isotonic bacteriostatic water (containing 0.9% sodium chloride) to minimize injection site reactions. Plain BAC water works but may cause more sting. Store lyophilized powder refrigerated or frozen; once reconstituted, keep at 2–8°C and use within 4–6 weeks. Protect from light and temperature fluctuations.

### What is known about combining SS-31 with NAD+?

Yes, and they're synergistic. SS-31 repairs membrane structure so electrons flow cleanly, which reduces the NAD+ burn rate (less oxidative damage means less NAD+ spent on repair). Adding NAD+ support (IV or IM, not just oral) ensures the cofactor is available when the membrane can finally use it efficiently. This is the basis of the MOTS-c + SS-31 + NAD+ mitochondrial stack.

### What side effects have been reported with SS-31?

Most people experience mild transient effects: brief warmth or flushing, occasional nausea that resolves quickly, and fatigue early in the daily phase (especially if baseline mitochondrial function is poor). Serious adverse events are rare in published data. The long-term Barth syndrome trials showed acceptable tolerability over years of treatment.

### What evidence supports cyclical versus continuous SS-31 use?

Use an 8–12+ week course rather than a scheduled on/off cycle. Run 6 mg daily through week 8. After that, continue daily if the response is still building or move to 2–3× weekly when the objective becomes maintenance. The week-12-to-24 human trajectory makes week 12 a reassessment point, not a mandatory stop³.

### What is the regulatory and access status of SS-31?

For Barth syndrome, elamipretide (Forzinity) is now FDA-approved and available through specialty pharmacies. For other uses, it remains investigational and is available through research peptide suppliers, select compounding pharmacies, or expanded-access programs through clinicians. Quality varies significantly among research suppliers; third-party testing and a certificate of analysis are the standard provenance checks.

---

---

## SS-31 for Mitochondrial Stability {#mitochondrial-stability}

This section covers SS-31 as an **add-on module** for advanced injury recovery—designed to layer on top of the [5-compound base protocol](/content/injury-recovery-peptide-protocol) when relapse under load is the limiting factor.

The final bottleneck in injury recovery often isn't tissue structure—it's **mitochondrial instability under stress**. The pattern is progress for a few sessions, then a flare. Fatigue becomes the limiter, not mechanics. The injury site reads as biologically _reactive_, not simply weak.

SS-31 (Elamipretide) stabilizes mitochondrial output so repair can consolidate instead of repeatedly re-inflaming.

### Injury Recovery At a Glance

|                      |                                                          |
| -------------------- | -------------------------------------------------------- |
| **Target**           | Cardiolipin on inner mitochondrial membrane              |
| **Goal**             | Reduce ROS spikes under stress; stabilize ATP production |
| **When to use**      | Repair is structurally complete but relapses under load  |
| **Establishment dose** | 6 mg daily through week 8                                |
| **Extension dose**     | 6 mg daily or 2–3× weekly after week 8                   |
| **Course**             | 8–12+ weeks                                              |

**Key principle:** SS-31 is not a "healing peptide"—it's a stability layer that makes existing repair hold under stress.

### Who This Is For

People who have:

1. Completed foundational repair (BPC-157/TB-500)—blood flow restored, tissue warm and supple
2. Established metabolic support (NAD+/GHK-Cu/KPV)—energy stable, collagen quality improving
3. Optimized hormonal timing (Tesamorelin if needed)—sleep-timed repair functioning
4. **But still relapse under load**—progress stalls when training intensity increases

### Signs You Need This

- Progress for 2–3 sessions, then flare without obvious cause
- Post-session soreness/stiffness is disproportionate to load
- Recovery becomes unpredictable despite consistent programming
- Energy crashes specifically during periods of higher training stress
- The injury site feels "reactive" rather than just weak
- Fatigue becomes the limiter, not mechanics or pain
- The pattern points to metabolic stress reactivating inflammation

### Signs This Isn't the Right Next Step

- Tissue is still cold, stiff, or poorly perfused → More BPC-157/TB-500
- Energy crashes even at rest → More NAD+
- Sleep is still disrupted → [Tesamorelin](/content/tesamorelin#injury-recovery)
- Neural symptoms persist (burning, tingling) → [ARA-290](/content/ara-290#nerve-pain)
- The issue is clearly programming (too much volume/intensity) → Adjust training first

### What Role Does the Base Protocol Play Before SS-31?

**Recommended but not required.** SS-31 works best when layered on top of foundational repair:

| Scenario                                      | Recommendation                                                           |
| --------------------------------------------- | ------------------------------------------------------------------------ |
| Acute injury (<4 weeks)                       | Start with [BPC-157 + TB-500](/content/wolverine-stack)  |
| Chronic injury with multiple bottlenecks      | Start with [5-compound base protocol](/content/injury-recovery-peptide-protocol) |
| Relapse under load is the clear limiter       | SS-31 can be added to established protocol                               |
| Already running base protocol, flares persist | Add SS-31                                                                |

SS-31 stabilizes mitochondrial function during stress—but if tissue lacks blood flow (needs BPC-157), cellular mobility (needs TB-500), or baseline energy (needs NAD+), there's less to stabilize. The foundation matters.

**However:** With clear evidence of mitochondrial dysfunction (confirmed by functional testing, or a pattern of post-exertional crashes that doesn't respond to other interventions), SS-31 can be used earlier in the protocol stack.

### The Physiologic Problem

Most rehab ends when pain resolves, but durable recovery often fails at a quieter bottleneck: **mitochondrial instability during stress**.

When mitochondria leak electrons (during spikes in training stress, poor sleep, under-fueling, or aggressive rehab progression), damaging byproducts (reactive oxygen species) rise, inflammatory signaling reactivates, and the result is the classic "two steps forward, one step back."

| Before SS-31                                     | After SS-31                                  |
| ------------------------------------------------ | -------------------------------------------- |
| Energy production variable; drops under stress   | More consistent output during daily establishment |
| Residual ROS → micro-inflammation after sessions | Lower electron leak, fewer ROS spikes        |
| Collagen remodeling starts but doesn't "stick"   | More predictable consolidation week-to-week  |
| Fatigue and guarding return with load            | Less relapse pressure from metabolic stress  |
| Reactive, oscillating progress                   | Stable progression tolerance                 |

### How SS-31 Works for Injury Recovery

SS-31 is a mitochondria-targeted peptide that localizes to the inner mitochondrial membrane and interacts with **cardiolipin** — the lipid that holds the electron transport chain together¹.

### Cardiolipin: The Core Problem

Cardiolipin is a lipid found almost exclusively on the inner mitochondrial membrane. It anchors the energy-producing protein complexes and their connecting shuttle (cytochrome c) in position, enabling efficient electron transfer¹. When cardiolipin is damaged — from aging, inflammation, injury, or repeated stress — the membrane loosens and the machinery drifts apart.

The consequences cascade: electrons leak from the chain and generate damaging byproducts instead of energy, energy output drops per unit of oxygen consumed, and if damage is severe enough, the connecting shuttle detaches entirely and can trigger cell death signaling (apoptosis)¹. Meanwhile, the inflammation switch (NF-κB) activates, compounding the damage.

This is why tissue feels "tired" even when structure is intact. The machinery is inefficient.

### What SS-31 Does for Injury Recovery

SS-31 concentrates 1,000–5,000× in mitochondria within minutes of administration¹. It binds cardiolipin and:

| Mechanism                                                    | Effect                                            | What You Notice                         |
| ------------------------------------------------------------ | ------------------------------------------------- | --------------------------------------- |
| Membrane stabilization (cardiolipin binding)                 | Tightens energy chain, reduces electron leak      | More ATP per unit oxygen                |
| Blocks oxidative damage cascade                              | Prevents cardiolipin oxidation chain reaction      | Less oxidative damage during stress     |
| Damaging byproduct reduction (ROS)                           | Direct scavenging + source reduction              | Soreness resolves faster post-session   |
| Activates long-term adaptation signaling (SIRT1)             | Enhanced mitochondrial growth signaling            | Better long-term adaptation             |
| Inflammation switch suppression (NF-κB)                      | Reduced inflammatory reactivation                 | Fewer "mystery flares" after heavy days |
| Preserves the cell's main antioxidant (glutathione)          | Maintains antioxidant capacity                    | More resilience under repeated stress   |

**The practical claim is not "SS-31 heals tendons."** The claim is: mitochondrial output becomes steadier under stress, which reduces relapse pressure during progressive loading. The tissue has the energy it needs to consolidate repair instead of repeatedly re-inflaming.

### Injury Recovery Dosing Protocol

**The base protocol continues** (BPC-157 + TB-500 + NAD+ + GHK-Cu + KPV). This module adds:

| Phase        | Dose    | Frequency   | Duration   |
| ------------ | ------- | ----------- | ---------- |
| **Establish** | 6 mg | Daily | Weeks 1–8 |
| **Extend** | 6 mg | Daily or 2–3× weekly | Week 9 onward |

Establishment: consistency matters more than dose escalation.
Extension: stay daily while the response is building; move to 2–3× weekly once stable.

**Route:** IV or IM in clinical settings; SubQ may be used with appropriate guidance

### Weekly Schedule (Example)

**Base protocol continues as normal**, with SS-31 layered on:

**Establishment Phase (Weeks 1–8)**

| Add-On | Mon  | Tue  | Wed  | Thu  | Fri  | Sat  | Sun  |
| ------ | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| SS-31  | 6 mg | 6 mg | 6 mg | 6 mg | 6 mg | 6 mg | 6 mg |

**Maintenance Option (After Week 8, Once Stable)**

| Add-On | Mon  | Tue | Wed  | Thu | Fri  | Sat | Sun |
| ------ | ---- | --- | ---- | --- | ---- | --- | --- |
| SS-31  | 6 mg | —   | 6 mg | —   | 6 mg | —   | —   |

### Weeks 1–2

- **What's happening:** Cardiolipin stabilization begins
- **What you notice:** Post-session recovery feels cleaner
- **Challenge:** Consistency is the variable; changes rarely show this early

### Weeks 2–4

- **What's happening:** ATP efficiency improves
- **What you notice:** Load tolerance rises; fewer flares
- **Decision point:** Keep the daily establishment phase running

### Weeks 4–8

- **What's happening:** Consolidation under load
- **What you notice:** Progress becomes predictable
- **Cadence:** Continue daily through week 8; after that, frequency can drop to 2–3× weekly once stable

### What "Working" Looks Like

- Post-session flare frequency drops
- Recovery becomes predictable (less "random" soreness/stiffness)
- Rehab load can climb without triggering multi-day setbacks
- Tissue feels stable rather than reactive

A transient "boost" without any change in flare patterns points away from mitochondrial instability as the limiter.

### Injury Recovery Implementation Notes

- **Timing:** Morning or pre-training typically works well
- **Route:** IV or IM (clinical settings); SubQ may be used with appropriate guidance
- **Mixing:** Inject alone; do not mix with other peptides in same syringe
- **Adjustment:** When injection site irritation or fatigue shows up, frequency comes down before dose

### Signs of Success

- No residual pain/swelling after heavy training weeks
- Strength and endurance equal or better than pre-injury
- Sleep quality consistently high
- Energy stable even with stacked work/life stress

### Maintenance Options

When all criteria are met:

- **Still improving after week 8:** Continue 6 mg daily
- **Stable after week 8:** Move to 6 mg 2–3× weekly
- **At week 12:** Reassess rather than stopping automatically; improvement continued through week 24 before flattening in the human Barth extension³
- **Simpler maintenance:** NAD+ support plus lifestyle if that's sufficient

### Conditioning Support: Optional Add-On

After SS-31 establishes mitochondrial stability, some people add **MOTS-c** and **L-Carnitine** for conditioning capacity:

| Compound        | Role                                      | When to Add                                  |
| --------------- | ----------------------------------------- | -------------------------------------------- |
| **MOTS-c**      | Flips the cellular exercise switch (AMPK), builds new mitochondria | When tissue is stable but work capacity lags |
| **L-Carnitine** | Fatty acid transport, fat-burning support (β-oxidation)            | Same—capacity is the limiter, not stability  |

This is optional and appropriate only after structural repair is complete and stable under load. When adding MOTS-c/L-Carnitine increases flare-ups, the pattern is to return to SS-31 stability first.

### Injury Recovery FAQ

**What is SS-31, and what evidence supports it in injury recovery?**

SS-31 (Elamipretide) is a mitochondria-targeted peptide that partitions into the negatively charged lipid surfaces of the inner mitochondrial membrane, cardiolipin among them¹. Cardiolipin helps hold the electron transport chain in position — when it is damaged, electrons leak and create oxidative stress instead of ATP. SS-31 changes the lipid environment those complexes sit in, and in model systems more oxygen becomes energy and less becomes damaging byproducts.

**Which injury-recovery contexts have been studied with SS-31?**

SS-31 is an advanced protocol for people who have completed foundational repair (BPC-157/TB-500), metabolic support (NAD+/GHK-Cu/KPV), and hormonal timing (Tesamorelin if needed)—but still experience relapse under load. It's for the "almost healed, but keeps flaring" pattern where tissue is structurally sound but reactive to stress.

**How do SS-31 and NAD+ differ?**

NAD+ is a redox cofactor—it carries electrons in the metabolic pathways that generate ATP. SS-31 targets the mitochondrial membrane structure itself, stabilizing the electron transport chain so those electrons don't leak. They work through different mechanisms and can be used together: NAD+ provides the substrate, SS-31 ensures the machinery runs efficiently.

**What subjective effects have been reported with SS-31?**

The reported pattern: post-session flare frequency drops, recovery becomes predictable instead of oscillating, training load climbs without triggering multi-day setbacks, energy feels steadier under stress, and soreness resolves faster.

**How long does an SS-31 cycle last?**

The course runs 8–12+ weeks. Use 6 mg daily through week 8, then continue daily while the response is still building or move to 2–3× weekly once stable. Week 12 is a reassessment point rather than an automatic stop.

**How is persistent symptom flaring evaluated after SS-31 begins?**

Persistent flares usually trace to one of seven things:

1. Inconsistent dosing or timing
2. A limiter that isn't actually mitochondrial (neural, hormonal, or programming instead)
3. The eight-week daily establishment phase was cut short
4. Training intensity too aggressive — a load no compound offsets
5. Nerve symptoms, where [ARA-290](/content/ara-290#nerve-pain) is the targeted layer
6. Disrupted sleep/GH timing, where [Tesamorelin](/content/tesamorelin#injury-recovery) is the targeted layer
7. An earlier protocol layer that still needs adjustment

**What is known about combining SS-31 with Tesamorelin or ARA-290?**

Yes. They address different bottlenecks:

- **SS-31:** Mitochondrial stability under load
- **[Tesamorelin](/content/tesamorelin#injury-recovery):** GH timing and sleep-timed repair
- **[ARA-290](/content/ara-290#nerve-pain):** Small-fiber nerve healing

These can be combined when multiple limiting factors are present. They work through independent pathways and don't interfere with each other.

---

## Related Topics

- [MOTS-c Guide](/content/mots-c) — exercise mimetic for metabolic adaptation
- [NAD+ Guide](/content/nad-guide) — essential cofactor for mitochondrial function
- [Pinealon Guide](/content/pinealon) — neuroprotective peptide targeting oxidative stress in neurons
- [Mitochondrial Stack](/content/mito-stack-protocol) — SS-31 + MOTS-c + NAD+ combined
- [Tesamorelin Guide](/content/tesamorelin) — GH-axis support for energy and recomposition
- [GLP-1 Comparison](/glp-1/compounds) — metabolic interventions (SS-31 supports during rapid fat loss)
- [BPC-157 Guide](/content/bpc-157) — Foundational vascular repair that precedes SS-31 in injury protocols
- [TB-500 Guide](/content/tb-500) — Cellular mobility — layer before SS-31 mitochondrial support
- [Reconstitution Guide](/content/reconstitution) — How to prepare SS-31 vials with isotonic BAC water
- [GHK-Cu Guide](/content/ghk-cu-skin) — Collagen and matrix quality — often runs alongside SS-31
- [GLOW & KLOW Protocol](/tools/klow-dosage-calculator) — Multi-peptide protocol where SS-31 is an advanced add-on
- [Injury Recovery Protocol](/content/injury-recovery-peptide-protocol) — SS-31 for stalled healing when NAD+ alone isn't enough
- [Retatrutide Guide](/content/retatrutide) — Triple-agonist GLP-1 — SS-31 supports during high oxidative flux
- [ARA-290 Guide](/content/ara-290) — For neuropathic symptoms that persist after structural repair

## References

¹ Mitochondrial-interface mechanism review — SS-31 is an aromatic-cationic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH₂) that associates with cardiolipin-rich and other anionic membrane interfaces and changes cardiolipin/cytochrome-c and respiratory behavior in model systems: Szeto HH, Liu S. _Int J Mol Sci_ 2025. [PMC11816484](https://pmc.ncbi.nlm.nih.gov/articles/PMC11816484/)

² Barth syndrome randomized trial — The 12-week TAZPOWER crossover missed both primary endpoints; open-label continuation followed: Thompson WR, Hornby B, Manuel R, et al. _Genet Med_ 2021. [Nature](https://www.nature.com/articles/s41436-020-01006-8)

³ TAZPOWER long-term extension — 168-week open-label Barth data. In the more severely affected subgroup, 6MWT improvement increased from week 12 to week 24, then remained essentially flat through weeks 36 and 48: Thompson WR, Manuel R, Batzner A, et al. _Genet Med Open_ 2024. [PMID: 38602181](https://pubmed.ncbi.nlm.nih.gov/38602181/)

⁴ ATP production in aging muscle — Single IV dose increased skeletal-muscle ATP production in selected older adults: Roshanravan B, Liu SZ, Ali AS, et al. _PLoS ONE_ 2021. [PMC8282018](https://pmc.ncbi.nlm.nih.gov/articles/PMC8282018/)

⁵ Failing human heart tissue — Ex vivo elamipretide exposure improved mitochondrial respiration in human myocardium: Sabbah HN, Gupta RC, Kohli S, et al. _JACC Basic Transl Sci_ 2019. [DOI: 10.1016/j.jacbts.2018.12.005](https://doi.org/10.1016/j.jacbts.2018.12.005)

⁶ Primary mitochondrial myopathy — MMPOWER-3; neither co-primary endpoint separated from placebo in the pooled population: Karaa A, Haas R, Goldstein A, et al. _Neurology_ 2023. [PMID: 37268435](https://pubmed.ncbi.nlm.nih.gov/37268435/)

⁹ FDA clinical-pharmacology and approval record — SPISC-101 administered 6 mg SubQ daily for seven days to healthy adults and measured parent and metabolite PK. The same review documents Forzinity's 2025 accelerated approval for Barth syndrome: [FDA integrated review](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/215244Orig1s000IntegratedR.pdf)

### Foundational Reviews

⁷ Sabbah HN, Gupta RC, Kohli S, et al. "Chronic therapy with elamipretide (MTP-131), a novel mitochondria-targeting peptide, improves left ventricular and mitochondrial function in dogs with advanced heart failure." *Circ Heart Fail.* 2016 Feb. [PMID 26839394](https://pubmed.ncbi.nlm.nih.gov/26839394/)

⁸ Siegel MP, Kruse SE, Percival JM, et al. "Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice." *Aging Cell.* 2013 Oct. [PMID 23692570](https://pubmed.ncbi.nlm.nih.gov/23692570/)

¹⁰ Onset and offset timecourse — In aged mice, diastolic function measures were unchanged at 4 weeks of SS-31 and significantly improved at 8 weeks versus controls; contractile function (fractional shortening) did not change at either point. After treatment stopped, the improvement was maintained at 2 weeks and had fallen by roughly half at 4 weeks. Dosing was continuous subcutaneous infusion: Chiao YA, Zhang H, Sweetwyne M, et al. _eLife_ 2020. [PMID 32648542](https://pubmed.ncbi.nlm.nih.gov/32648542/)

¹¹ Retatrutide hepatic oxidation — Sanyal AJ, et al. measured liver-fat and β-hydroxybutyrate changes: [10.1038/s41591-024-03018-2](https://doi.org/10.1038/s41591-024-03018-2). Pearson MJ, et al. measured the accompanying lipid and metabolite fingerprint: [10.1210/clinem/dgag201](https://doi.org/10.1210/clinem/dgag201). These establish the Retatrutide FAO signal; no trial has tested SS-31 as the downstream support layer.